Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.33 |
| ▸ | SMARCA2 | P51531 | 2/20 | 0.33 |
| ▸ | SMARCA4 | P51532 | 2/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | PREP | P48147 | 1/20 | 0.31 |
| ▸ | FAP | Q12884 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20012788 | 0.84 | OPRM1 (0.51) | OPRM1SMARCA2SMARCA4PDE4BPDE4D | |
| SCHEMBL20012579 | 0.80 | OPRM1 (0.38) | OPRM1SMARCA2SMARCA4PDE4BPDE4D | |
| SCHEMBL20012905 | 0.80 | PIK3CD (0.36) | OPRM1ROCK2PRKG1TRPA1 | |
| SCHEMBL19991709 | 0.76 | PDE4B (0.41) | OPRM1ROCK2PRKG1SMARCA2SMARCA4 | |
| SCHEMBL18038663 | 0.76 | OPRM1 (0.50) | OPRM1ROCK2PDE4BPDE4D | |
| SCHEMBL30606886 | 0.76 | OPRM1 (0.50) | OPRM1ROCK2PDE4BPDE4D | |
| SCHEMBL20009020 | 0.75 | DRD3 (0.39) | OPRM1HRH3HTR6 | |
| SCHEMBL20009027 | 0.72 | CYP11B2 (0.35) | OPRM1TRPA1 | |
| SCHEMBL18038762 | 0.72 | GPR119 (0.46) | — | |
| SCHEMBL20008965 | 0.72 | OPRM1 (0.47) | OPRM1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | SMARCC1, SMARCC2, SMARCA4 | OPRM1 2267/4885ROCK2 1903/4885PRKG1 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.